CRISPR and Gene Editing in Drug Development: A Revolution in Precision Medicine
DOI:
https://doi.org/10.63682/jns.v14i27S.6428Keywords:
CRISPR, gene editing, precision medicine, drug development, Cas9, genetic disorders, CAR-T therapy, base editing, prime editing, personalized medicine, synthetic biology, biotechnology, genome engineering, bioethics, infectious diseases, agriculture, AI in genomicsAbstract
The discovery and implementation of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology have transformed the landscape of biotechnology and precision medicine. As a revolutionary gene-editing tool, CRISPR enables targeted, efficient, and cost-effective modification of DNA, offering promising therapeutic interventions for a wide range of genetic and acquired diseases. This article provides an in-depth overview of CRISPR’s origins, mechanisms, and applications in drug development, from treating genetic disorders and enhancing cancer immunotherapies to accelerating drug discovery and developing tools against infectious diseases. It also addresses ethical considerations, regulatory frameworks, and future innovations such as base and prime editing. By exploring current trends and interdisciplinary applications, this article underscores the pivotal role CRISPR plays in shaping the future of medicine, agriculture, and synthetic biology
Downloads
Metrics
References
Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096
Barrangou, R., & Marraffini, L. A. (2014). CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity. Molecular Cell, 54(2), 234–244.
Frangoul, H., Altshuler, D., Cappellini, M. D., et al. (2021). CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. New England Journal of Medicine, 384, 252–260.
Maeder, M. L., & Gersbach, C. A. (2016). Genome-editing Technologies for Gene and Cell Therapy. Molecular Therapy, 24(3), 430–446.
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 533(7603), 420–424.
Anzalone, A. V., et al. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 576, 149–157.
Cox, D. B. T., Platt, R. J., & Zhang, F. (2015). Therapeutic genome editing: prospects and challenges. Nature Medicine, 21, 121–131.
Zhang, F., Wen, Y., & Guo, X. (2014). CRISPR/Cas9 for genome editing: progress, implications and challenges. Human Molecular Genetics, 23(R1), R40–R46.
Ledford, H. (2015). CRISPR, the disruptor. Nature, 522, 20–24.
National Academies of Sciences, Engineering, and Medicine. (2017). Human Genome Editing: Science, Ethics, and Governance. The National Academies Press
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
